Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued
Reference number: GID-TA10315
Dear Consultees and Commentators
As you will be aware the Department for Health and Social Care has asked NICE to conduct an appraisal of durvalumab with tremelimumab for untreated metastatic urothelial cancer.
Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations. Further information regarding the scheduling of this appraisal will be available in due course.